Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Published byEmery Patterson Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January."— Presentation transcript:

1 Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January of the specified year. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

2 Figure 5 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 10–14 years. Vertical dotted lines, January of the specified year. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

3 Figure 6 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese infants aged <1 year. Vertical dotted lines, January of the specified year. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

4 Figure 7 Monthly all-cause (A-C) mortality rates among Japanese children (age, 1–4 years) and elderly persons (age, 65–69 years). Vertical dotted lines, January of the specified year. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

5 Table 1 Influenza virus types and subtypes and excess mortality rates associated with influenza epidemics in Japan, 1974–2003. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

6 Figure 8 A, Estimated annual numbers of influenza vaccine doses administered versus annual excess all-cause (A-C) mortality rates among young children (age, 1–4 years; A) and annual excess pneumonia and influenza (P&I) mortality rates among young children (B) in Japan. During 1975–1994, almost all influenza vaccine doses were used for mass vaccination of schoolchildren, whereas after 1994, most influenza vaccine doses were used for young children and for elderly persons (age, >65 years). See Methods for an explanation of how data were calculated. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

7 Table 2 Monthly peaks of influenza-like illness (ILI) cases, all-cause deaths, and pneumonia and influenza (P&I) deaths among young children. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

8 Figure 1 Annual numbers of doses of influenza vaccine distributed in Japan during 1970–2003. Between 1970 and 1994, almost all vaccine doses were used for mass vaccination of schoolchildren (age, 6–15 years), whereas after 1994, vaccine doses were mainly used for vaccination of young children (age, 1–4 years) and of elderly persons (age, 60–69 years). From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

9 Figure 3 Peak monthly all-cause and pneumonia and influenza (P&I) mortality rates during 1972–1989 (A) and 1990–1999 (B) From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

10 Figure 2 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among young Japanese children aged 1–4 years. Vertical dotted lines, January of the specified year. From: Mass Vaccination of Schoolchildren against Influenza and Its Impact on the Influenza-Associated Mortality Rate among Children in Japan Clin Infect Dis. 2005;41(7): doi: /432938 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

Download ppt "Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January."

Similar presentations

U.S. Influenza Surveillance 2004 - 2005 Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.

U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.
CHILD MORTALITY IN AFRICA.  In the year 2006, for the first time since mortality data have been gathered, annual dates among children under the age of.

CHILD MORTALITY IN AFRICA.  In the year 2006, for the first time since mortality data have been gathered, annual dates among children under the age of.
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:
Contributions to Life Expectancy at Birth Change in Life Expectancy at Birth 1900-401940-601960-90 Total change 15.96.45.1 Change attributable to: Infant.

Contributions to Life Expectancy at Birth Change in Life Expectancy at Birth Total change Change attributable to: Infant.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of Influenza Vaccination on Seasonal Mortality.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of Influenza Vaccination on Seasonal Mortality.
Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010  Koh Cheng Thoon, Chia Yin Chong,

Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010  Koh Cheng Thoon, Chia Yin Chong,
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Figure 1 Overview of Markov model for infected total hip arthroplasty

Figure 1 Overview of Markov model for infected total hip arthroplasty
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
WHO Operational Plan for RSV Surveillance Pilot

WHO Operational Plan for RSV Surveillance Pilot
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.

Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.
Figure 1. Disposition of study participants, by group. Data are no

Figure 1. Disposition of study participants, by group. Data are no
Department of Sociology Population Studies Center

Department of Sociology Population Studies Center
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Similar presentations

Ads by Google